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Serotonin, 5-hydroxytryptamine, is a systemic bioactive amine that acts in the gut and brain. As a
substrate of myeloperoxidase in vitro, serotonin is oxidized to tryptamine-4,5-dione (TD), which is highly
reactive with thiols. In this work, we successively prepared a monoclonal antibody to quinone-modiﬁed
proteins and found that the antibody preferentially recognizes the TD–thiol adduct. Using the antibody,
we observed that the chloride ion, the predominant physiological substrate for myeloperoxidase in vivo,
is not competitive toward the enzyme catalyzed serotonin oxidation process, suggesting that serotonin is
a plausible physiological substrate for the enzyme in vivo. Immunocytochemical analyses revealed that
TD staining was observed in the cytosol of SH-SY5Y neuroblastoma cells while blot analyses showed that
some cellular proteins were preferentially modiﬁed. Pull-down analyses conﬁrmed that the cytoskeletal
proteins tubulins, vimentin, and neuroﬁlament-L were modiﬁed. When pure tubulins were exposed to
micromolar levels of synthetic TD, self-polymerization was initially enhanced and then suppressed.
These results suggest that serotonin oxidation by myeloperoxidase or the action of other oxidants could
cause functional alteration of cellular proteins, which may be related to neurodegeneration processes or
irritable bowel syndrome.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Serotonin, which is a well-known monoamine neurotransmit-
ter, has multifunctional bioactivity including modulation of in-
testinal movements and blood clotting. Serotonin in brain induces
biosignals via serotonin receptors on the cellular membrane. These
bioactivities have been intensively investigated since the discovery
of serotonin in the 1930s. However, there are few reports on
serotonin oxidation. Serotonin is oxidized by superoxide [1] orB.V. This is an open access article u
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Kato),
yogo.ac.jp (N. Kitamoto),myeloperoxidase [2], forming a reactive quinone, tryptamine-4,5-
dione (TD), and a dimer of serotonin. The dimer of serotonin is
formed by copper oxidation [3], a respiratory burst of activated
microglia [4] or activated neutrophils [2]. TD covalently reacts
with the thiol [5,6] and inactivation of enzymes via the formation
of quinone adducts has been reported [7,8]. Neutrophils, which
contain myeloperoxidase in their azurophilic granules, or puriﬁed
myeloperoxidase causes aggregation of the protein [9]. Stimulation
of polymorphonuclear leukocytes (PMNs) with serotonin in-
creased serotonin binding to PMN proteins [10]. These reports
suggest that covalent modiﬁcation of serotonin-derived species on
protein molecules might be triggered by myeloperoxidase activity
in vivo. A computer-aided docking study showed that serotonin is
a plausible substrate of myeloperoxidase [11]. Myeloperoxidase
may contribute to the development of Alzheimer's disease (AD) as
suggested by its expression in the brain of AD patients where it is
also co-localized with Aβ protein [12], which is one possible
initiator for AD. Taken together, this information supports the idea
that myeloperoxidase could oxidize serotonin in the brain.
In a previous study, we also detected the in vitro formation of a
covalent adduct of a serotonin moiety with a model thiol protein,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), using ser-
otonin or biotinylated serotonin as the substrate for myeloperox-
idase [13]. The adduction of the serotonin oxidation products withnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Scheme for adduct formation of serotonin oxidation products onto a protein.
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serotonin radical by use of N-acetyl-L-cysteine (NAC) as a model
of a thiol residue. When protein was used instead of NAC, quinone
adducts but not serotonin–thiol adducts were identiﬁed on the
protein molecule (Fig. 1). In addition, the adduction of TD has been
shown to generate a tryptamine-4,5-diol–protein adduct, which
rapidly converts to the corresponding quinone adduct [5]. How-
ever, the molecular mechanism and biological signiﬁcance of
protein modiﬁcation by serotonin oxidation products has not been
fully investigated because of the lack of an analytical tool for
detection of modiﬁcation in a cell or tissue.
Herein, we report the study of cytoskeletal proteins as targets
of TD by pull-down methods using a novel antibody to TD-
modiﬁed proteins. The modiﬁcation on the proteins was also
induced using biotinylated TD probe and the biotin-incorporated
proteins were then captured with avidin linked agarose.Materials and methods
Materials
Serotonin and dithiothreitol (DTT) were purchased from Wako
Pure Chemicals. Human myeloperoxidase was obtained from
Planta Natural Products. Xanthine oxidase from bovine milk
(XOD; type X4500) and GAPDH (from rabbit) were purchased
from Sigma. Acetaldehyde was purchased from Merck. CanGet-
Signal-1 and -2 were purchased from TOYOBO. Tris[2-carbox-
yethyl] phosphine hydrochloride (TCEP) was purchased from
Nacalai Tesque Inc. Biotinylated serotonin (serotonin–biotin) was
prepared by reacting sulfo-NHS-LC-biotin (Thermo Scientiﬁc) with
serotonin [13].
Synthesis of tryptamine-4,5-dione
TD was freshly synthesized with minor modiﬁcations [7].
Brieﬂy, 1 mg of serotonin was dissolved in 500 ml of water and
then added to potassium nitrosodisulfonate (Aldrich), which is
known as Fremy's reagent. After 1 min, the mixture was applied to
a Supelco Discovery DSC-18 (C18) solid phase extraction column
(500 mg, SPE). The SPE column was washed with 2 ml of water,
and the purple colored compound was eluted with 1% formic acid
in water/CH3CN (25/75) and then collected. The TD concentration
was measured by absorbance at 350 nm using its extinction
coefﬁcient [14]. TD–biotin was synthesized from a serotonin–
biotin conjugate according to the method referenced above.
Preparation of immunogen
Keyhole limpet hemocyanin (Imject KLH, Pierce) was used as a
carrier protein. Before exposure to TD, the KLH was treated with
DTT to regenerate the thiol moiety as described previously [15].
Brieﬂy, 20 mg of KLH was dissolved in 4 M guanidine-HCl (pH 8.5)
and 20 mg of DTT was then added. After saturation with N2, the
solution was sealed and then stirred at room temperature over-
night in the dark. The solution was dialyzed against phosphate-buffered saline (PBS) at 4 °C for 1 day with 3 exchanges of PBS. The
dialyzed KLH (2 mg/ml) was incubated with synthetic TD (1 mM)
in PBS and after 1 h, the solution was dialyzed at 4 °C against PBS
overnight with two exchanges of PBS. As the positive control
antigen, commercial bovine serum albumin (BSA; lipid-free) was
exposed to TD and then further processed as described above. The
samples were washed with 4 volumes of ice-cold acetone and
centrifuged at 4 °C for 10 min. The precipitates were dissolved in
PBS and stored at 80 °C.
Preparation of monoclonal antibody
A total of 150 ml of immunogen (1 mg/ml) was mixed with
350 ml of PBS and 500 ml of Freund's complete adjuvant. A total of
250 ml of the mixture (ﬁnal 150 mg/ml of KLH) was injected into a
Balb/c mouse. After 1 month, the mouse was boosted with 250 ml
of the immunogen, which was mixed with 150 ml of the KLH
(1 mg/ml) and 350 ml of PBS with 500 ml of Freund's incomplete
adjuvant. Two weeks after the second immunization, the mouse
was immunized into the tail vein and the abdominal cavity with
250 ml of the KLH in PBS. Three days after the ﬁnal immunization,
the spleen from the mouse was fused with myeloma cells by the
polyethylene glycol method as described previously [16]. Hybri-
domas were selected by using TD-modiﬁed BSA as an antigen by
noncompetitive enzyme-linked immunosorbent assay (ELISA) as
described below. Finally 5 clones (1B7, 1A11, 2E12, 1E3, and 1D11)
were obtained. The antibodies were collected from serum free
culture medium (Hybridoma-SFM, GIBCO) by cultivation of the
clones and then puriﬁed by a Protein G column (Hi-Trap IgG, GE
Healthcare). All antibodies were determined as IgG1 subclass,
which was estimated by immunochromatography (Iso-gold Rapid
Mouse-Monoclonal Isotyping Kit, Bioassay Works). Antibody 1B7
was mainly used for the following analyses.
Characterization of antibody
Competitive ELISA
TD–BSA (50 ml, 0.01 mg/ml in PBS) was coated onto a microtiter
plate (Nunc, Maxisorp) and kept at 4 °C overnight. The plate was
washed with 200 ml of PBS containing 0.05% Tween 20 (TPBS)
three times. Competitor (50 ml) and antibody (50 ml) were dis-
solved in 1% BSA–PBS, and then were added into the wells of the
plate. The plate was incubated for 2 h at 37 °C and then treated
with anti-mouse IgG-horseradish peroxidase (HRP) for 1 h at room
temperature. The color development was achieved using 3,3′,5,5′-
tetramethylbenzidine reagent (TMB; Kirkegaard & Perry Labora-
tories Inc.) and terminated by the addition of 1 M phosphoric acid.
Noncompetitive ELISA
Samples (50 ml, 0.01 mg/ml in PBS) were coated at 4 °C onto the
microtiter plate overnight. The plate was washed with 200 ml of
TPBS 3 times, and 100 ml of antibody in 1% BSA–PBS was added and
incubated at 37 °C for 2 h. The binding of the antibody was
evaluated by using the anti-mouse IgG antibody labeled with
HRP. The color development was done by TMB as described
previously. In some cases, alkaline phosphatase (AP)-labeled
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IgG–HRP conjugate in order to avoid artifact peroxidase activity
derived from the antigen, myeloperoxidase. In this case, after the
reaction of antibody with antigen, anti-mouse IgG–AP conjugate in
the CanGetSignal-2 reagent was added and incubated for 1 h. The
plate was then treated with p-nitrophenyl phosphate in 10%
diethanolamine–HCl buffer (pH 9.8) containing 0.5 mM MgCl2.
Modiﬁcations of protein by oxidized serotonin
Serotonin and its related compounds including biotinylated
serotonin were used as substrates of the myeloperoxidase system
and the modiﬁed proteins were analyzed by slot-blot/quinone
staining and ELISA. The system contained myeloperoxidase
(50 nM), XOD (1/1000), substrate (0.1 mM) and GAPDH (0.7
mg/ml) in 50 mM phosphate buffer containing 1 mM diethylene-
diaminetetraacetic acid (pH 7.4) and reactions were started by
adding acetaldehyde (10 mM). After 10 min, the reaction was
terminated by the addition of allopurinol (0.1 mM) and the
modiﬁed proteins were separated from the reaction mixture by a
microspin-column (Bio-Rad).
Detection of quinones on slot-blotted membrane by redox-cycling
staining
Proteins were blotted with a slot-blot apparatus (Bio-Dot SF,
Bio-Rad). Brieﬂy, 200 ml of GAPDH (0.01 mg/ml in PBS) was blotted
onto a polyvinylidene diﬂuoride membrane and washed with
200 ml of PBS. The membrane was removed from the blot appara-
tus and washed with water for 5 min and then soaked with
nitroblue tetrazolium (NBT)/alkaline glycinate buffer (NBT 4
mg/20 ml alkaline–glycinate buffer) for 2 h in the dark [17]. The
membrane image was analyzed by ImageJ software (version 1.41).
Estimation of biotin incorporation into protein
Samples (50 ml, 0.01 mg/ml in PBS) were coated at 4 °C onto the
microtiter plate for overnight. The plate was washed with 200 ml of
TPBS three times and 100 ml of streptavidin–HRP polymer (Ultra-
sensitive, Sigma) in 1% BSA–PBS was added and incubated at 37 °C
for 1 h. The color development was done using TMB as described
above.
Identiﬁcation of antigen from the reaction mixture of tryptamine
dione and N-acetyl cysteine
Synthetic TD (5 mM) was mixed with NAC (5 mM) in phosphate
buffer, pH 7.4. After 15 min, the reaction mixture was injected into
an HPLC equipped with a Develosil Combi-RP column
(20100 mm, Nomura Chemical Co., Ltd.) using 0.1% acetic acid/
CH3CN (9/1) as an eluent at a ﬂow rate of 5 ml/min. The eluate was
monitored using a photodiode array detector and then fractio-
nated every minute (5 ml each). The fractions were concentrated
with a centrifugal evaporator and used for competitive ELISA as
described above. Some fractions were also analyzed by liquid
chromatography mass spectrometry using API3000 (AB Sciex)
and Agilent 1100 with a Develosil ODS-SR-5 column
(2150 mm, Nomura Chemical Co., Ltd.) with the same solvent
at a ﬂow rate of 0.2 ml/min. A positive Q1 scan from 50 to 600 and
Q1-multiple ion scan at 352.1 were performed.
Preparation of thiol-proteins
DTT–treated thiol–refreshed BSA (DTT–BSA)
BSA (25 mg) was dissolved in 2.25 ml of water. To the solution,
250 ml of DTT (3 mg/ml) was added and reacted for 2 h. The DTT–treated BSA was concentrated using the centrifugal ﬁltration
apparatus Vivaspin 6 (7500g, 4 °C, 30 min). The remaining protein
was further centrifuged with an additional 5 ml of 0.1 M phos-
phate buffer (pH 7.4) to wash off the residual DTT. The protein was
then collected and immediately used.
N–Ethylmaleimide–treated free thiol–blocked BSA (NEM-BSA)
10 mg of NEM (Sigma) was added to 1 ml of BSA (10 mg in
0.1 M phosphate buffer, pH 7.2) and reacted for 2 h at room
temperature. The reaction mixture was applied to a PD-10 gel
ﬁltration column (GE Healthcare) and fractionated. The fractions
containing protein was further applied to the Vivaspin 6 (7500g,
4 °C, 30 min) and concentrated protein was collected and stored at
20 °C until use.
Free thiol estimation
To estimate free thiols in the protein, 100 ml of 5, 5′-dithiobis(2-
nitrobenzoic acid) dissolved at 3 mg/ml of water, 400 ml of phos-
phate buffer, and 500 ml of protein (2 mg/ml in phosphate buffer)
were mixed and incubated at room temperature for 15 min in the
dark. The absorbance at 412 nm was measured and the thiol
concentration was estimated using the extinction coefﬁcient of
13,600 M-1 cm1.
Cultured cells
The neuroblastoma cell line SH-SY5Y was obtained from DS
Pharma-Biomedical Company (ECACC). The cells were maintained
in Dulbecco's modiﬁed Eagle's medium/Ham's F12 (Ham's F-12/
DMEM) containing 15% fetal bovine serum.
Immunocytochemistry
SH-SY5Y cells were cultivated on an eight-well chamber slide
(Lab-Tek II, Nunc). The slide was washed and replaced with serum-
free DMEM medium in order to exclude hypoxanthine, which is
included in the Ham's F-12/DMEM medium and is known to be a
substrate of XOD. Myeloperoxidase (50 nM), XOD (1/1000), acet-
aldehyde (10 mM), and serotonin (0.1 mM) were added to the well
and further incubated for 30 min in a CO2 incubator. As a positive
control, 50 mM of synthetic TD was also added to the well. The
wells were washed with PBS and ﬁxed in methanol at 20 °C for
10 min. After treatment with 0.5% Triton X100 in PBS for 10 min at
room temperature, the slide was washed with PBS and reacted
with the 1B7 antibody (2 mg/ml) in PBS containing 1% BSA for 1 h
at room temperature. The slide was washed and incubated with
FITC-conjugated anti-mouse immunoglobulin and peritoneum
iodide (for nuclei) in PBS at room temperature for 1 h in the dark.
The slide was then washed, and an antifade reagent (ProLong Gold,
Invitrogen) was added before analysis by confocal microscopy.
Immunoprecipitation by antibody beads
SH-SY5Y cells were exposed to various concentrations of
synthetic TD for 15 min in serum-free DMEM and then washed
with ice-cold PBS. The cells were lysed by Mammalian Protein
Extraction Reagent (M-PER) with HALT protease inhibitor cocktail
(Pierce) and then immunoprecipitated by 1B7 mAb which had
been conjugated to NHS-activated Sepharose 4 Fast Flow beads
(GE Healthcare). The precipitates were eluted with 0.1 M glycine–
HCl (pH 3.0) and then neutralized by 1 M aqueous Tris. The sample
was applied to gels for further analyses as described below.
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SH-SY5Y cells were exposed to synthetic TD–biotin and lysed as
described above. The biotin-tagged protein was precipitated by
avidin–agarose (A9207, Sigma). The precipitates were applied to
gels and further analyzed as described below.
Gel and Western blot analysis
Protein samples were mixed with sodium dodecyl sulfate (SDS)
loading buffer without 2-mercaptoethanol. The proteins were
applied to two gels for SDS polyacrylamide gel electrophoresis.
In one gel, the protein was stained with SYPRO Orange or SYPRO
Ruby (Invitrogen) according to the manufacturer's recommenda-
tions. The protein in the other gel was electrotransferred onto an
Immobilon-P transfer membrane (Millipore). The membrane was
then blocked with 4% Block Ace (Dainihon Sumitomo Seiyaku)
aqueous solution for 1 h at room temperature. After washing the
membrane three times for 10 min each with TTBS (Tris–buffered
saline containing 0.05% Tween-20), the membrane was incubated
with the primary antibody (0.5 mg/ml dilution in TTBS or CanGet-
Signal-1) for 1 h at room temperature. After washing again, the
membrane was incubated with anti-mouse IgG–HRP conjugate at
a 1:10,000 dilution in TTBS or CanGetSignal-2 for 1 h at room
temperature. After washing, the membrane was visualized using
ECL-Plus or ECL-prime detection reagent (GE Healthcare). The gel
images were captured by Lumino Image Analyzer LAS-1000plus
(FUJIFILM) and analyzed with Image Gauge software (ver. 3.4).
Polymerization assay of tubulin
The polymerization assay was performed using a commercial
Tubulin Polymerization Assay kit (Cytoskeleton Inc.). Porcine
tubulin was incubated with or without synthetic TD at 37 °C and
the changes in optical density (O.D.) at 340 nm were recorded for
30 min with a microplate reader according to the manufacturer's
recommendations. As a control, a tubulin solution was kept at 4 °C
for 30 min. After the microplate reader measurement, the intact
sample and TCEP-reduced sample were collected and applied to
gels. Blot analyses were performed as shown in the above section.
TCEP was added to the sample at a concentration of 25 mM for
30 min at room temperature.Fig. 2. Comparison of the formation of antigenicity with chemical adduction of
indoles treated with myeloperoxidase. (A) The chemical adduction of indoles on the
protein molecule was evaluated by quinone redox staining following the reaction
and slot blotting. (B) The immunoreactivity was estimated by ELISA followed by the
reaction of indoles with the myeloperoxidase/xanthine oxidase/acetaldehyde en-
zyme system. The bar shows the relative intensity of the staining to serotonin
(substrate). The structures of four substrates for myeloperoxidase are shown.Results
Preparation and characterization of an antibody to TD-modiﬁed
protein
To conﬁrm the covalent modiﬁcation of cellular proteins by TD,
a monoclonal antibody to a TD-modiﬁed protein was prepared as
described in Materials and methods. Among the obtained anti-
bodies, 1B7 mAb was further characterized. As TD is known to
preferentially react with thiols [5], we prepared three types of BSA,
DTT–treated BSA, NEM–treated BSA, and native BSA and the effect
of free thiol on the generation of immunoreactivity by exposure of
TD was examined. The relative amounts of free thiols on BSA
varied depending on its type, at 9.7, 0.2, and 1 for DTT–treated
BSA, NEM–treated BSA, and native BSA, respectively. The reactivity
of antibody toward the BSAs after exposure to TD increased with
an increase in the free thiol content of the BSAs (Fig. S1A),
suggesting that the antibody recognized the TD-modiﬁed thiol
moiety. The adduction of TD on the protein molecules, which was
evaluated by using TD–biotin, was observed even with the thiol-
depleted BSA, NEM–BSA (Fig. S1B). This suggests that the major
epitope of the TD-modiﬁed protein recognized by the antibody is aTD-modiﬁed thiol moiety but TD adduction itself is not restricted
to cysteine residues, i.e., amino residues could possibly be targeted
by TD.
Epitope analysis of the established antibody
To further conﬁrm the epitope of 1B7 mAb, TD and NAC were
reacted and the products were then fractionated by HPLC (Fig. S2A
and B). The antibody reacted with the fraction containing two
products (retention times at 14 and 16 min). From the UV–vis scan
and the mass spectrometry analysis, the product at 16 min was
identiﬁed as the adduct of NAC with TD, 7-S-(N-acetylcysteinyl)
tryptamine-4,5-dione [13]. The former product was unstable and
had the same 352 [MþH]þ ion as the latter product, 7-S-(N-
acetylcysteinyl)tryptamine-4,5-dione. This suggests that the for-
mer product is a transient diol-type adduct [5,6].
Comparison of immunoreactivity among modiﬁed proteins exposed to
myeloperoxidase-treated indoles
It has been reported that melatonin is also modiﬁed by
myeloperoxidase [18]. A metabolite of serotonin, 5-hydroxyindo-
leacetic acid (5HIAA), might be oxidized by myeloperoxidase as
well. On the basis of structural similarity, 5-hydroxytryptophan
(5OH-Trp), the precursor of serotonin, is another plausible target
of myeloperoxidase. Melatonin, 5HIAA, 5OH-Trp and serotonin
were treated with the myeloperoxidase system in the presence of
GAPDH and the modiﬁed proteins were then blotted onto a
membrane. After exposure to the myeloperoxidase system, 5HIAA,
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nones as estimated by the results from the NBT-reduction reagent,
indicating that the quinone moieties were formed from the three
indoles, in particular 5HIAA, but not melatonin (Fig. 2A). When the
immunoreactivities against quinone-modiﬁed GAPDH were exam-
ined, the antibody only reacted with GAPDH exposed to myelo-
peroxidase-treated serotonin (Fig. 2B). This suggests that the
established antibody speciﬁcally recognizes oxidized serotonin-
derived protein modiﬁcations.
Effect of chloride ion on enzymatic serotonin-derived protein
modiﬁcation
Myeloperoxidase is known to generate reactive hypochlorous
acid (HOCl) from the substrates hydrogen peroxide and chloride
ion under physiological conditions. When the buffer concentration
of chloride ion was varied in the enzymatic serotonin oxidation
system, the immunoreactivity against modiﬁed proteins was the1500 25 50 75 100 125
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1
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m
Fig. 3. Effect of chlorine ion on myeloperoxidase-dependent protein modiﬁcation
by serotonin. GAPDH was exposed to the myeloperoxidase/xanthine oxidase/
acetaldehyde system in phosphate buffer (pH 7.4) with various concentrations of
NaCl. The modiﬁcation of GAPDH with TD generated by the enzyme was estimated
by ELISA.
Fig. 4. Immunocytostaining of neuroblastoma SH-SY5Y cells incubated with myeloper
treated in serum-free medium for 30 min with the enzyme system (complete, A), the om
also shown in B. After the treatment, cells were ﬁxed with methanol and permeabilize
followed by secondary antibody (FITC labeled, green). The nuclei were stained with perit
D, without acetaldehyde; E, without myeloperoxidase; F, without xanthine oxidase; and
the reader is referred to the web version of this article.)same even at 150 mM NaCl, which is the physiological concentra-
tion of chloride ion (Fig. 3). This suggests that serotonin oxidationoxidase/acetaldehyde/xanthine oxidase/serotonin or synthetic TD. The cells were
ission of the component (C–F), or 50 mM synthetic TD (G). The untreated cells are
d with 0.5% Triton X-100. The cells were then incubated with the antibody (1B7),
oneum iodide (red). A, complete; B, control (untreated cells); C, without serotonin;
G, TD (50 mM). (For interpretation of the references to colour in this ﬁgure legend,
Fig. 5. Dose-dependent formation of TD-modiﬁed cellular proteins. SH-SY5Y cells were
exposed to various concentrations of synthetic TD and the cells were then lysed.
Separated proteins were stained with SYPRO Orange. The proteins were blotted onto a
membrane and quinone-modiﬁed proteins were stained by the speciﬁc antibody 1B7.
Y. Kato et al. / Redox Biology 2 (2014) 983–990988and successive modiﬁcation of protein are not competitive with
the enzymatic generation of HOCl.
Generation of cellular antigen in neuroblastoma cells treated with
serotonin
TD may be a neurotoxin because it has a highly reactive
quinone moiety. Proteins in SH-SY5Y neuroblastoma cells were
modiﬁed by the serotonin oxidation system, which included the
complete enzyme system and substrates (Fig. 4). This suggested
that the serotonin oxidation product, TD, modiﬁed cellular
proteins. Positive immunostains were also observed in cell
lysates and some bands seemed to be selectively modiﬁed by
TD in a dose-dependent manner (Fig. 5). The intensities of
positive bands by immunostaining were not matched with those
by protein staining, indicating that the adduction onto proteins
was not random.Fig. 6. Identiﬁcation of TD-modiﬁed proteins with speciﬁc antibodies. (A) Immu-
noprecipitation of TD-modiﬁed proteins by 1B7 mAb-beads. (B) Precipitation of
biotinylated proteins by avidin-beads. The cells were exposed to 100 mM of
synthetic TD or TD–biotin and then lysed. The pull-down assay was performed as
described in Materials and methods. The precipitated proteins were stained with
SYPRO Ruby.
Fig. 7. Effect of TD on polymerization of tubulins. Tubulins were incubated with
guanosine triphosphate in the presence or absence of TD, and the aggregation and/
or polymerization of tubulins was conﬁrmed by monitoring the O.D. at 340 nm.Identiﬁcation of target proteins
Immunoprecipitation using the 1B7 speciﬁc antibody was then
performed. Since the amounts of modiﬁed proteins were not
enough to analyze by mass spectrometry, we used antibodies to
some cytoskeletal proteins, which have been reported as predo-
minant targets for some nucleophilic reagents [19–22]. As shown
in Fig. 6A, the cytoskeletal proteins ⍺,β-tubulins (55 kDa) and
vimentin (58 kDa) were detected on the blot membrane. Neuro-
ﬁlament-L (70 kDa) was weakly detected. GAPDH (35 kDa) and β-
actin (50 kDa), which are often modiﬁed by a nucleophilic reagent,
were not identiﬁed in the precipitate.
The cells were exposed to TD–biotin and the quinone-modiﬁed
proteins tagged by the biotin moiety were then precipitated by
using avidin beads. Some proteins, especially those 40–70 kDa,
were separated in the gel (Fig. 6B). ⍺,β-Tubulins, vimentin,
neuroﬁlament-L, and β-actin were also identiﬁed on the blotted
membrane.
Polymerization assay of tubulins exposed to TD
The protein modiﬁcations by serotonin oxidation products may
induce changes in the function of the proteins. As shown in Fig. 6A
and B tubulins were clearly modiﬁed by TD. Therefore, in the
current study, we focused on tubulins, which were allowed to self-
polymerize in the presence of guanosine triphosphate, and then
the effect of TD on polymerization of tubulin was examined.
During incubation, tubulins were polymerized/self-assembled in
a time-dependent fashion and the addition of 200 mM TD to
tubulins signiﬁcantly enhanced the polymerization, particularly
during the initial phase (Fig. 7). Fifty micromolar TD also promoted
the polymerization at ﬁrst, but within 10 min, the control tubulin
polymerization proceeded faster. As shown in Fig. 8, highly
aggregated tubulin was observed at the top of the gel (stacking
gel) and quinone-modiﬁed proteins were detected in TD-treated
tubulins even after reduction with TCEP. These results suggest that
the larger than expected increase in O.D. at 340 nm by TD was due
to the nonspeciﬁc aggregation of tubulins rather than the poly-
merization/self-assembly of tubulins, which is a well-organized
event (Fig. 9).
Fig. 8. Immunoblot analyses of tubulin exposed to TD. The reaction was done as
described in the legend to Fig. 7. The samples were then applied with or without
reduction by TCEP. The protein was stained with SYPRO Orange and quinone-
modiﬁed tubulins were then detected by blot analyses.
Fig. 9. Plausible scheme for modulation of tubulin aggregation by TD exposure.
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Serotonin has several beneﬁcial biological activities in vivo but,
it may also contribute to the development of some diseases such
as irritable bowel syndrome or depression. Perfusion of serotonin
causes protein carbonylation in the heart, possibly through ROS
production and inhibition of monoamine oxidase B [23]. Serotonin
in the plasma of patients with vascular dementia is normally
higher than that in the control [24]. These ﬁndings suggest that
increased plasma levels of serotonin with carotid atherosclerotic
plaques may be involved in the pathogenesis and progression of
vascular dementia. When serotonin is oxidized by various oxidants
and peroxidases, the highly reactive quinone, TD, is then formed
[1,2]. However, there are only a few reports on TD generation
in vivo. For example, in zebra ﬁsh treated with methylmercury,
extracellular serotonin was decreased while TD increased [25].
Thus, it is likely that the reactive quinone may contribute to
certain biological events.
Serotonin is one possible substrate for peroxidases in vivo. As
shown in Fig. 3, the generation of a quinone adduct was consis-
tently observed in the presence of various concentrations of
chloride ion, which should be the main substrate of myeloperox-
idase in vivo. This suggests that chloride ion does not compete
with serotonin as a substrate of myeloperoxidase.
In a previous study, we found by mass spectrometry that
myeloperoxidase uses serotonin as the substrate and the formedproduct, TD, covalently reacts with the peptide containing Cys152
and Cys156 in human GAPDH [13]. The adduction of quinone was
also conﬁrmed by biotin-labeled serotonin as a substrate of
myeloperoxidase or TD–biotin followed by detection with strepta-
vidin-peroxidase or streptavidin–AP. In the current study, we have
successfully developed an immunochemical method to detect
quinone–protein adducts by preparing a novel antibody. The TD–
thiol adduct is considered to be the predominant epitope for the
antibody (Fig. S2) but the antibody may also cross-react with a TD-
amine adduct (Fig. S1A).
TD is a putative neurotoxin. However, it is difﬁcult to detect TD
in biological samples because of its high reactivity. Once conju-
gated with biomolecules, the adduct becomes relatively stable
[13]. The established antibody may prove useful for identifying the
contribution of TD to the development/progression of some
diseases including serotonin-related diseases. In this study, the
target proteins were isolated using both antibody beads and avidin
beads with biotinylated TD as a model compound. Whereas the
signals for TD–biotin were stronger than those from antibody
beads, similar results were obtained. TD–biotin is a good probe for
screening target proteins even though it is a synthetic compound.
Our novel antibody should be useful to identify serotonin-derived
oxidative modiﬁcations.
Previous papers have reported that these cytoskeletal proteins
are modiﬁed by nucleophiles in cells [19–22]. We immunochemi-
cally identiﬁed cytoskeletal proteins as targets for the quinone in
neuronal cells but could not verify the identities of these proteins
by mass spectrometry because there was insufﬁcient precipitated
protein. Though our previous study showed that GAPDH, as a thiol
model protein, was modiﬁed by TD in vitro [13], we could not
detect TD-modiﬁcation of GAPDH in the cells. The proteins on the
blotted membrane, in particular, in the higher molecular weight
region, remain to be identiﬁed.
We found that polymerization of tubulins is affected by TD
treatment even at micromolar levels, suggesting that TD modiﬁca-
tion of a protein changes the nature and/or function of the protein.
Modiﬁcation of functional proteins by reactive TD may play an
important part in some serotonin-related diseases.
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